Cited by 648Osteoarthritis Treatment and MechanismsProtease and Inhibitor MechanismsProteoglycans and glycosaminoglycans research

Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development

Open access
Little, C. B., Barai, A., Burkhardt, D., Smith, S. M., Fosang, A. J., Werb, Z., Shah, M., Thompson, E. W.·2009·Arthritis & Rheumatism

Abstract

Objective: To investigate the role of matrix metalloproteinase 13 (MMP‐13; collagenase 3) in osteoarthritis (OA). Methods: OA was surgically induced in the knees of MMP‐13–knockout mice and wild‐type mice, and mice were compared. Histologic scoring of femoral and tibial cartilage aggrecan loss (0–3 scale), erosion (0–7 scale), and chondrocyte hypertrophy (0–1 scale), as well as osteophyte size (0–3 scale) and maturity (0–3 scale) was performed. Serial sections were stained for type X collagen and the MMP‐generated aggrecan neoepitope DIPEN. Results: Following surgery, aggrecan loss and cartilage erosion were more severe in the tibia than femur ( P < 0.01) and tibial cartilage erosion increased with time ( P < 0.05) in wild‐type mice. Cartilaginous osteophytes were present at 4 weeks and underwent ossification, with size and maturity increasing by 8 weeks ( P < 0.01). There was no difference between genotypes in aggrecan loss or cartilage erosion at 4 weeks. There was less tibial cartilage erosion in knockout mice than in wild‐type mice at 8 weeks ( P < 0.02). Cartilaginous osteophytes were larger in knockout mice at 4 weeks ( P < 0.01), but by 8 weeks osteophyte maturity and size were no different from those in wild‐type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild‐type and knockout mouse joints. Conclusion: Our findings indicate that structural cartilage damage in a mouse model of OA is dependent on MMP‐13 activity. Chondrocyte hypertrophy is not regulated by MMP‐13 activity in this model and does not in itself lead to cartilage erosion. MMP‐13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP‐13 inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.25002

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Little, C. B., Barai, A., Burkhardt, D., Smith, S. M., Fosang, A. J., Werb, Z., Shah, M., & Thompson, E. W.
Affiliations
  • The University of Sydney (AU)
  • Royal Children's Hospital (AU)
  • University of California, San Francisco (US)
  • The University of Melbourne (AU)
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-11-30
Volume
60
Issue
12
Pages
3723-3733
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2060951121
Cited by
642
References
54
Citations by year
2026: 26 · 2025: 36 · 2024: 39 · 2023: 38 · 2022: 43 · 2021: 42 · 2020: 59 · 2019: 42 · 2018: 35 · 2017: 46 · 2016: 41 · 2015: 42 · 2014: 34 · 2013: 36 · 2012: 29
FWCI
18.84
Type
journal article
Language
en
Open access
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Arthritis Australia
  • National Institutes of Health
  • Medical Research Council
  • National Health and Medical Research Council (384414)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR046238, R01AR046238)
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
Keywords
matrix metalloproteinase-13, collagenase-3, osteoarthritis, cartilage erosion, chondrocyte hypertrophy, osteophytes, type X collagen, MMP-13 inhibitors
MeSH terms
Animals, Arthritis, Experimental, Calcinosis, Cartilage, Articular, Femur, Hypertrophy, Joints, Male, Osteoarthritis, Tibia, Mice, Knockout, Chondrocytes, Mice, Matrix Metalloproteinase 13, Aggrecans, Osteophyte

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review